Author

J. Frenel

h-index 35 View on Semantic Scholar

We have 3 of 280 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Phase II study of cabozantinib in recurrent or metastatic cervical cancer after progression on platinum-based chemotherapy (CABOCOL).

OBJECTIVE The antiangiogenic pathway is an effective target for recurrent uterine cervical carcinoma (rCC). This study evaluated the safety and efficacy of cabozantinib monotherapy for rCC. PATIENTS & METHODS This open-label phase II study (NCT04205799) enrolled patients with rCC who previously received platinum-base...

E. Coquan, R. Vion, Emeline Colomba-Blamemble et al. · Gynecologic Oncology · 0 citations

Open access Oct 2026

Clinical features associated with exceptional response on first-line anti-HER2-based therapy for metastatic breast cancer: real-world data from the ESME national cohort

Clinical variables alone had limited predictive value, supporting the need for molecular and immune biomarkers to better identify this subgroup of patients with HER2-positive metastatic breast cancer.

T. Grinda, M. Carton, S. Morganti et al. · Breast · 0 citations

Open access Sep 2026

Chemotherapy outcomes in human epidermal growth factor receptor 2-low, hormone receptor-positive metastatic breast cancer: Insights from the French multicenter ESME database.

BACKGROUND The human epidermal growth factor receptor 2 (HER2)-targeted therapy trastuzumab deruxtecan has demonstrated significantly improved efficacy versus chemotherapy in HER2-low or -ultralow, hormone receptor (HR)-positive metastatic breast cancer (mBC) following endocrine therapy (ET). This study describes curre...

W. Jacot, P. Macouillard, Su-Yuan Zhang et al. · Breast · 0 citations